A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)
Authors:
- 22 January 2024
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 182, 75-81
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (P30CA008748)
- National Institutes of Health
This publication has 23 references indexed in Scilit:
- Integrated Molecular Characterization of Uterine CarcinosarcomaCancer Cell, 2017
- Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registryAnnals of Oncology, 2015
- Second-Line Therapy for Endometrial Cancer: The Need for Better OptionsJournal of Clinical Oncology, 2015
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)The Journal of Molecular Diagnostics, 2015
- HER2‐Positive Endometrial Cancer Subtype Carries Poor PrognosisClinical and Translational Science, 2014
- Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast TumorsJournal of Clinical Oncology, 2012
- Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group studyGynecologic Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association With Outcome in a Large Cohort of Surgically Staged PatientsJournal of Clinical Oncology, 2006
- Her-2/neu Overexpression and Amplification in Uterine Papillary Serous CarcinomaJournal of Clinical Oncology, 2004